Q-omics provides the consensus-scored ZFP3 profile across patient tissues and cancer cell-line models. ZFP3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZFP3 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ZFP3 RNA expression shows 20,021 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where ZFP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP3 survival associations across molecular data types. ZFP3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP3 RNA expression–survival associations across cancer types. High ZFP3 expression shows favorable associations in HNSC, KIRC, PAAD, CESC, LUAD and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZFP3 RNA expression.
This table summarizes ZFP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZFP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP3 shows lower tumor expression in THCA, COAD, KIRC, UCEC, LUAD and KICH. The THCA box plot shows higher ZFP3 RNA expression in normal versus tumor tissue (log2 FC = −1.541, t-test p < 0.001).
This table shows molecular features associated with ZFP3 in patient tissues and cancer cell lines. In patient samples, ZFP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
